Evaluation of the performance of DNA microarrays in detecting MTB drug resistance in sputum samples from patients with culture-positive pulmonary tuberculosis
WANG Yue, SUN Ying, SUN Bing-qi
Shenyang 10th People’s Hospital, Shenyang 110044, China
Abstract:To evaluate the efficiency of a DNA microarray chip assay in detecting rifampicin and isoniazid drug resistance genes in sputum samples from patients with tuberculosis cultures, we collected and detected sputum samples from 389 patients with suspected pulmonary tuberculosis. The sensitivity, specificity and consistency of the chip method in detecting drug resistance to RIF and INH, and MDR-TB were evaluated, with the MGIT 960 test as the reference standard. If the results were inconsistent with those of the reference standard, the GenoType MTBDRplus technique from the WHO was used for verification. Drug resistance was detected with the chip method in 334 sputum samples with positive results detected by liquid culture, including two NTM positive cases and nine negative cases. Compared with those of the reference standard, the chip method’s sensitivity, specificity and Kappa value were 92.4%, 97.7% and 0.90, respectively, in the rifampicin resistance test, and 82.6%, 99.2% and 0.86, respectively, in the isoniazid resistance test. In patients with MDR-TB, the results were consistent with those of the liquid drug sensitivity test. In the new cases, the Kappa value was 0.95, and the sensitivity was 95.5%, values significantly better than those of the previously treated cases. In addition, 22 inconsistent results were analyzed with GenoType MTBDRplus ver 2.0, it is considered that the detection limit and drug resistance mechanism, heterogeneous drug resistance and multiple infection are the main reasons for the inconsistent results of genotype and phenotype or two molecular methods. The chip method for the detection of rifampicin and isoniazid resistance genes in sputum samples of patients with positive cultures has good sensitivity, specificity and consistency, and can quickly detect resistance and MDR-TB. This method provides a rapid and effective chemotherapy reference scheme for clinical patients, particularly new cases.
王悦, 孙颖, 孙炳奇. DNA微阵列芯片技术检测培阳肺结核患者痰样本中结核分枝杆菌耐药性的价值[J]. 中国人兽共患病学报, 2021, 37(2): 109-114.
WANG Yue, SUN Ying, SUN Bing-qi. Evaluation of the performance of DNA microarrays in detecting MTB drug resistance in sputum samples from patients with culture-positive pulmonary tuberculosis. Chinese Journal of Zoonoses, 2021, 37(2): 109-114.
[1] Unissa AN, Subbian S, Hanna LE, et al.Overview on mechanisms of isoniazid action and resistance in Mycobacterium tuberculosis[J]. Infect Genet Evol,2016,45:474-492.DOI:10.1016/j.meegid.2016.09.004 [2] Campbell EA, Korzheva N, Mustaev A, et al.Structural mechanism for rifampicin inhibition of bacterial rna polymerase[J].Cell,2001,104:901-912.DOI:10.1016/s0092-8674(01)00286-0 [3] Blanchard JS.Molecular mechanisms of drug resistance in Mycobacterium tuberculosis[J]. Annu Rev Biochem, 1996,65:215-239.DOI:10.1146/annurev.bi.65.070196.001243 [4] Espasa M, Salvado M, Vicente E, et al.Evaluation oftheVersaTREK system compared to the bactec MGIT 960 system for first-linedrug susceptibility testing of Mycobacterium tuberculosis[J]. J Clin Microbiol,2012,50(2):488-491.DOI: 10.1128/JCM.06432-11 [5] Kim SJ.Drug-susceptibility testing in tuberculosis:methods and reliability of results[J]. Eur Respir J,2005,25(3):564-569. DOI:10.1183/09031936.05.00111304 [6] 赵艳林,逄宇.结核病实验室检验规程[M].北京:人民卫生出版社,2015. [7] Markelov ML, Shipulin GA, Pokrovskii VI.Biochip technologies-newprospects in diagnosis of human diseases[J]. Ter Arkh,2008,80(4):79-85.DOI:10.1080/02813430802542508 [8] Guo Y, Zhou Y, Wang C, et al.Rapidaccuratedetermination of multidrug resistance in M. Tuberculosis isolates andsputum using a biochip system[J]. Int J Tuberc Lung Dis, 2009,13(7):914-920.DOI: 10.1258/ijsa.2009.009146 [9] Zhu L, Liu Q, Martinez L, et al.Diagnostic value of Gene Chip for detection of resistant Mycobacterium tuberculosis in patientswith differing treatment histories[J]. J Clin Microbiol,2015,53(1):131-135.DOI: 10.1128/jcm.02283-14 [10] Tang P, Wang X, Shen X,et al.Use of DNA microarraychips for the rapid detection of Mycobacterium tuberculosis resistance torifampicin and isoniazid[J]. Exp Ther Med,2017,13:2332-8.DOI: 10.3892/etm.2017.4250 [11] Almeida Da Silva PE,Palomino JC.Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis:classical and new drugs[J].J Antimicrob Chemother,2011,66:1417-1430. [12] Maruri F,Sterling TR,Kaiga AW,et al.A systematic review of gyrase mutation associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system[J].J Antimicrob Chenother,2012,67:819-831. [13] da Silva PE,Von Groll A,Martin A,et al.Efflux as a mechanism for drug resistance in Mycobacterium tuberculosis[J].FEMS Immunol Med Microbiol,2011,63:1-9. [14] 刘元,周俊,崔晓利,等.基因芯片与线性探针技术检测涂阳肺结核患者痰标本MTB耐药性的价值[J].中国防痨杂志,2019,41(7):738-742. DOI:10.3969/j.issn.1000-6621.2019.07.007 [15] Abanda NN,Djieugoue JY,Lim E,et al.Diagnostic accuracy and usefulness of the Genotype MTBDRplus assay in diagnosing multidrug-resistant tuberculosis in Cameroon a cross-sectional study[J].BMC Infect Dis,2017,17(1):379. [16] 魏淑贞,林淑芳,林建,等.GenoType MTBDRplus快速检测耐多药结核分枝杆菌复合群临床分离株效果评价[J].中国人兽共患病学报,2015,31(8):728-732. DOI:10.3969/j.issn.1002-2694.2015.08.009 [17] Martin A,Herranz M,Ruiz Serrano MJ,et al.The clonal composition of Mycobacterium tuberculosis in clinical specimens could be modified by culture[J].Tuberculosis(Edinb),2010,90(3):201-207. [18] 高旭,李静,柳清云,等.异质性耐药对结核分枝杆菌表型和基因型耐药检测结果的影响[J]. 中华结核和呼吸杂志,2014,37(4):260-265.